Kygevvi (Doxecitine / Doxribtimine)

Kygevvi is a medicine for thymidine kinase 2 deficiency, a rare genetic disease that weakens the muscles. It is a powder mixed into a liquid and taken by mouth. It gives the body building blocks it needs to make healthy DNA inside the energy-making parts of muscle cells.

Brand names:Kygevvi
Medication

What people taking Kygevvi (Doxecitine / Doxribtimine) report

Every report comes from a Lived member, sent anonymously.

Have you tried Kygevvi (Doxecitine / Doxribtimine) for Mitochondrial Myopathies?

NameHow it went

About Kygevvi (Doxecitine / Doxribtimine)

What It's For

Kygevvi is a prescription medicine containing doxecitine and doxribtimine. It treats thymidine kinase 2 deficiency (TK2d), a rare inherited disease in which muscles gradually weaken because their cells cannot keep up their supply of mitochondrial DNA. Weakness often affects walking, swallowing and, over time, the muscles used for breathing, which is the most common cause of death in this disease. It is approved for adults and children whose symptoms began at age 12 or younger, and the studies included people whose diagnosis was confirmed by genetic testing. People whose symptoms started after age 12 have also been treated in small reports, but that is not an approved use. The approval rests on survival. In the studies, 3 of 78 treated people died, compared with 28 of 78 untreated people matched by the age their symptoms began. Because the untreated group came from medical records and published cases rather than a randomized trial, the size of the benefit is an estimate, but the difference was large.

How It Works

Mitochondria are the parts of a cell that turn food into usable energy, and they carry their own small set of DNA. Building and repairing that DNA requires a steady supply of raw materials called nucleosides. Thymidine kinase 2 is an enzyme that recycles two of them inside mitochondria. When the enzyme does not work, muscle cells run short, their mitochondrial DNA dwindles, and they produce less energy. Muscle, which uses a great deal of energy, is hit hardest. Doxecitine and doxribtimine are lab-made versions of those two nucleosides (deoxycytidine and deoxythymidine). Taken in large daily amounts, they are meant to supply enough raw material for muscle cells to rebuild their mitochondrial DNA. In mice with the disease, this restored mitochondrial DNA levels. Kygevvi does not correct the underlying gene, which is why it is taken continuously.

Dosage & Administration

Kygevvi comes as a powder in single-use packets. Each morning, the person taking it or a caregiver mixes a full day's supply with room-temperature water in the mixing bottle from the administration kit supplied by the pharmacy. The day's solution is divided into three doses taken about six hours apart, each with food, and measured with the kit's dosing cup or oral syringe rather than kitchen spoons. Any solution left after 16 hours, or after the third dose, is thrown away. It can also be given through most feeding tubes. The dose is based on body weight. Treatment starts at a lower level and is raised in steps, staying at least two weeks on each step, until the maintenance dose is reached if side effects allow. The amount of liquid therefore changes as a child grows or the dose is adjusted. If a dose is spit out or not fully taken, do not give another; wait for the next scheduled dose. A forgotten dose is different: take it when remembered, unless the next dose is due within two hours, and never take two doses together.

Side Effects

Diarrhea is the most common side effect and affected about seven in ten people in the main study. Abdominal pain and vomiting are also common, and vomiting happens more often in children than in adults. These problems are the most frequent reason the dose is lowered: about one in five people needed a dose reduction for diarrhea, and a small number stopped treatment because of it. Diarrhea was serious enough to require a hospital stay in two children. The care team can usually manage digestive side effects by pausing treatment or stepping back to a lower dose, then building up again. Diarrhea or vomiting that lasts more than a few days should be reported promptly, because it can lead to dehydration and loss of body salts, especially in small children. Signs of dehydration (much less urine or fewer wet diapers, a dry mouth, no tears, unusual sleepiness), or a child who cannot keep fluids or doses down, call for contacting the care team the same day.

Interactions & Warnings

Kygevvi can raise liver enzymes, the blood tests (called ALT and AST) that rise when liver cells are under strain. In the studies this happened more often in children than in adults. TK2d itself can also raise these numbers, so a blood test of liver enzymes and bilirubin (a pigment that builds up when the liver is not clearing it) is done before starting to set a baseline, then at least once a year. Contact the care team promptly about loss of appetite, stomach pain, dark urine or yellowing of the skin or eyes. If the liver appears affected, treatment is usually paused until the tests settle; a few people have had to stop for good when the problem came back. There is no information on Kygevvi in pregnancy or breastfeeding. Mitochondrial muscle diseases themselves carry higher risks in pregnancy, such as preterm birth and preeclampsia, so anyone pregnant or planning a pregnancy should work through the decision with the specialist team. Blood levels of the medicine rise when the kidneys work poorly, and no adjusted dose has been worked out, so kidney problems are worth raising before treatment.

What to Expect

Kygevvi is a long-term, daily treatment, and the routine of mixing the solution each morning and spacing three doses with meals becomes part of daily life at home. The first weeks are spent stepping up the dose while watching for diarrhea and stomach upset. The proven benefit is longer survival. Whether, and how much, strength or breathing improves is less clear. Small reports describe some people walking farther or breathing better after months to years of treatment, but these were not controlled studies, and starting before major muscle loss is thought to matter. Follow-up usually involves a neuromuscular or mitochondrial disease specialist, regular checks of strength, breathing and growth, and yearly liver tests.

Questions to Ask Your Doctor

  1. 1.Given when symptoms started and how far the disease has progressed, what can we realistically hope Kygevvi will change?
  2. 2.How will we measure whether it is working, and how often will strength and breathing be tested?
  3. 3.What should we do at home if diarrhea or vomiting starts, and when should we call you?
  4. 4.How will the dose change as my child grows, and who helps us learn the mixing and dosing routine?
  5. 5.How do pregnancy plans, kidney problems or a feeding tube affect treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.